Market Closed -
Canadian Securities Exchange
20:56:09 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.54
CAD
|
-6.90%
|
|
-1.82%
|
+68.75%
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6.645
|
35.01
|
41.78
|
141.8
|
54.74
|
30.67
|
Enterprise Value (EV)
2 |
6.388
|
75.86
|
74.78
|
162.9
|
71.21
|
40.91
|
P/E ratio
|
-7.19
x
|
-1.02
x
|
-1.1
x
|
-21.5
x
|
4.98
x
|
223
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
13,541,656
x
|
1,108,196
x
|
3,924,889
x
|
1,659,621
x
|
1,061,535
x
|
EV / Revenue
|
-
|
29,339,830
x
|
1,983,212
x
|
4,507,810
x
|
2,159,079
x
|
1,416,161
x
|
EV / EBITDA
|
-
|
-6,651,972
x
|
33,633,726
x
|
16,934,190
x
|
6,562,329
x
|
7,215,664
x
|
EV / FCF
|
-16
x
|
-12
x
|
18.5
x
|
46.2
x
|
30.3
x
|
5.45
x
|
FCF Yield
|
-6.24%
|
-8.32%
|
5.4%
|
2.16%
|
3.3%
|
18.3%
|
Price to Book
|
77
x
|
2.16
x
|
3.08
x
|
5.78
x
|
1.56
x
|
0.89
x
|
Nbr of stocks (in thousands)
|
5,980
|
45,064
|
89,276
|
113,299
|
120,048
|
120,048
|
Reference price
3 |
1.111
|
0.7769
|
0.4680
|
1.252
|
0.4560
|
0.2554
|
Announcement Date
|
21/03/18
|
31/05/19
|
14/07/20
|
31/05/21
|
15/08/22
|
13/06/23
|
1USD in Million2CAD in Million3USD Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
2.586
|
37.71
|
36.13
|
32.98
|
28.89
|
EBITDA
|
-
|
-11.4
|
2.223
|
9.617
|
10.85
|
5.67
|
EBIT
1 |
-0.7057
|
-12.03
|
-1.181
|
7.522
|
9.755
|
4.298
|
Operating Margin
|
-
|
-465.16%
|
-3.13%
|
20.82%
|
29.58%
|
14.88%
|
Earnings before Tax (EBT)
1 |
-0.7736
|
-23.6
|
-28.84
|
-3.74
|
17.13
|
4.191
|
Net income
1 |
-0.7736
|
-23.6
|
-32.56
|
-6.106
|
10.92
|
0.2932
|
Net margin
|
-
|
-912.82%
|
-86.34%
|
-16.9%
|
33.1%
|
1.01%
|
EPS
2 |
-0.1546
|
-0.7613
|
-0.4245
|
-0.0582
|
0.0915
|
0.001143
|
Free Cash Flow
1 |
-0.3989
|
-6.31
|
4.039
|
3.522
|
2.347
|
7.501
|
FCF margin
|
-
|
-244.03%
|
10.71%
|
9.75%
|
7.12%
|
25.97%
|
FCF Conversion (EBITDA)
|
-
|
-
|
181.67%
|
36.62%
|
21.63%
|
132.31%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
21.5%
|
2,558.36%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/03/18
|
31/05/19
|
14/07/20
|
31/05/21
|
15/08/22
|
13/06/23
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
40.8
|
33
|
21.1
|
16.5
|
10.2
|
Net Cash position
1 |
0.26
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-3.582
x
|
14.84
x
|
2.19
x
|
1.518
x
|
1.807
x
|
Free Cash Flow
1 |
-0.4
|
-6.31
|
4.04
|
3.52
|
2.35
|
7.5
|
ROE (net income / shareholders' equity)
|
410%
|
-223%
|
-188%
|
-31.4%
|
45.2%
|
4.06%
|
ROA (Net income/ Total Assets)
|
-216%
|
-19.3%
|
-1.06%
|
7.22%
|
9.48%
|
4.47%
|
Assets
1 |
0.3582
|
122
|
3,063
|
-84.59
|
115.2
|
6.557
|
Book Value Per Share
2 |
0.0100
|
0.3600
|
0.1500
|
0.2200
|
0.2900
|
0.2900
|
Cash Flow per Share
2 |
0.0400
|
0.1500
|
0.0300
|
0.0500
|
0.0300
|
0.0200
|
Capex
|
-
|
0.21
|
0.51
|
0.23
|
2.56
|
0.44
|
Capex / Sales
|
-
|
8.24%
|
1.35%
|
0.63%
|
7.77%
|
1.53%
|
Announcement Date
|
21/03/18
|
31/05/19
|
14/07/20
|
31/05/21
|
15/08/22
|
13/06/23
|
|
1st Jan change
|
Capi.
|
---|
| +68.75% | 47.45M | | +40.09% | 6.16B | | -16.34% | 4.46B | | -7.11% | 3.27B | | +5.14% | 3.2B | | -0.18% | 2.6B | | +47.93% | 1.98B | | -7.15% | 1.7B | | +0.67% | 1.66B | | -8.73% | 1.61B |
Alternative Medicine
|